Palatin Technologies (NYSEAMERICAN:PTN – Get Free Report)‘s stock had its “buy” rating reaffirmed by investment analysts at HC Wainwright in a report issued on Thursday, Benzinga reports. They presently have a $17.00 price objective on the biopharmaceutical company’s stock.
Palatin Technologies Price Performance
PTN stock opened at $1.09 on Thursday. Palatin Technologies has a fifty-two week low of $0.68 and a fifty-two week high of $5.65.
Palatin Technologies (NYSEAMERICAN:PTN – Get Free Report) last issued its quarterly earnings data on Tuesday, October 1st. The biopharmaceutical company reported ($0.51) earnings per share (EPS) for the quarter. On average, research analysts forecast that Palatin Technologies will post -2.03 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Palatin Technologies
Palatin Technologies Company Profile
Palatin Technologies, Inc, a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder.
Featured Stories
- Five stocks we like better than Palatin Technologies
- Breakout Stocks: What They Are and How to Identify Them
- Texas Roadhouse Stock Steering for New Highs This Year
- Top Biotech Stocks: Exploring Innovation Opportunities
- Monopar Therapeutics Skyrockets 400% on Licensing Deal
- How to Use Stock Screeners to Find Stocks
- Tractor Supply Stock Pulls Back: A Prime Buying Opportunity
Receive News & Ratings for Palatin Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Palatin Technologies and related companies with MarketBeat.com's FREE daily email newsletter.